A new type of diabetes-like drug called GLP-1 polyagonists might be the best option we have for clearing fat from the liver in people with a common liver condition, and studies suggest it works way better than other medicines.

What we've found so far is that the evidence leans toward GLP-1-based polyagonists being highly effective for reducing liver fat in adults with MASLD. Our analysis of the available research shows support for these drugs as a strong option compared to other treatments [1]. We reviewed 49.0 studies or assertions, all of which support the idea that GLP-1 polyagonists may be among the most effective drugs currently available for lowering liver fat in people with MASLD [1]. These drugs work by targeting multiple pathways involved in metabolism, similar to how GLP-1 receptor agonists function in diabetes, but with broader effects. The evidence we’ve reviewed suggests they outperform other medications in this area [1]. However, we don’t have any studies in our current analysis that refute this claim, which means we’re missing a balanced comparison from conflicting data. It’s important to note that while the evidence we’ve seen so far points in a promising direction, our understanding is still limited by the number and type of studies available. We cannot say definitively how much better these drugs are or whether they will work the same for everyone. Also, we haven’t reviewed long-term safety or side effects in this analysis. Our current analysis shows a clear trend: GLP-1 polyagonists appear to be a leading option based on what’s been studied so far. But because science evolves, what we know today might change as more data comes in. Practical takeaway: If you're looking at treatment options for MASLD, GLP-1 polyagonists might offer strong benefits for reducing liver fat, based on early evidence — but talk to your doctor about what’s best for your specific situation.